Aerie Pharmaceuticals continues their work in dry eye and glaucoma markets

Aerie Pharmaceuticals has multiple clinical trials in the pipeline for dry eye and glaucoma.

Michelle Senchyna, PhD, VP Clinical Development and Medical Affairs for Aerie Pharmaceuticals, shares a brief update on those.

Key pipeline highlights:

• After a successful phase 2, AR-15512 (0.003%), Aerie's novel dry eye product candidate, advances to phase 3 later this quarter.
• In late March, a phase 4 program kicked off with Aerie's product Rocklatan, Aerie's FDA-approved once-daily eye drop for the treatment of glaucoma. The phase 4 study is seeking to show data to demonstrate that it is the most powerful one drop, once a day formulation for the treatment of glaucoma.